{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:11:15Z","timestamp":1784956275570,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40290-023-00509-4","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T03:02:18Z","timestamp":1703127738000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eliciting Exploratory Patient Preference Data: A Case Study in a Rare Disease"],"prefix":"10.1007","volume":"38","author":[{"given":"Kerrie-Anne","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredin","family":"Stoltenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Tarancon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"6","key":"509_CR1","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","volume":"19","author":"M Ho","year":"2016","unstructured":"Ho M, Saha A, McCleary KK, Levitan B, Christopher S, Zandlo K, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746\u201350. https:\/\/doi.org\/10.1016\/j.jval.2016.02.019.","journal-title":"Value Health."},{"key":"509_CR2","unstructured":"US FDA. Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. Guidance for Industry and Food and Drug Administration Staff. 2019. Available at: https:\/\/www.fda.gov\/media\/99769\/download. Accessed 27 Dec 2022."},{"issue":"7","key":"509_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jval.2019.11.009","volume":"23","author":"K Marsh","year":"2020","unstructured":"Marsh K, van Til JA, Molsen-David E, Juhnke C, Hawken N, Oehrlein EM, et al. Health preference research in Europe: a review of its use in marketing authorization, reimbursement, and pricing decisions-report of the ISPOR stated preference research special interest group. Value Health. 2020;23(7):831\u201341. https:\/\/doi.org\/10.1016\/j.jval.2019.11.009.","journal-title":"Value Health."},{"issue":"7","key":"509_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","volume":"24","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, Whichello C, Levitan B, Veldwijk J, Pinto CA, Donkers B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324\u201331. https:\/\/doi.org\/10.1016\/j.drudis.2019.05.001.","journal-title":"Drug Discov Today"},{"key":"509_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3389\/fphar.2019.01395","volume":"10","author":"E van Overbeeke","year":"2019","unstructured":"van Overbeeke E, Janssens R, Whichello C, Sch\u00f6lin Bywall K, Sharpe J, Nikolenko N, et al. Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. Front Pharmacol. 2019;10:1395. https:\/\/doi.org\/10.3389\/fphar.2019.01395.","journal-title":"Front Pharmacol"},{"issue":"1","key":"509_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40271-019-00401-x","volume":"13","author":"IL Hollin","year":"2020","unstructured":"Hollin IL, Craig BM, Coast J, Beusterien K, Vass C, DiSantostefano R, et al. Reporting formative qualitative research to support the development of quantitative preference study protocols and corresponding survey instruments: guidelines for authors and reviewers. Patient. 2020;13(1):121\u201336. https:\/\/doi.org\/10.1007\/s40271-019-00401-x.","journal-title":"Patient"},{"key":"509_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society. J Neurol. 2016;263:1473\u201394.","journal-title":"J Neurol"},{"key":"509_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.790834","volume":"12","author":"Z Song","year":"2022","unstructured":"Song Z, Zhang J, Meng J, Jiang G, Yan Z, Yang Y, et al. Different monoclonal antibodies in myasthenia gravis: a bayesian network meta-analysis. Front Pharmacol. 2022;12: 790834. https:\/\/doi.org\/10.3389\/fphar.2021.790834.","journal-title":"Front Pharmacol"},{"issue":"8","key":"509_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387. https:\/\/doi.org\/10.1007\/s40265-022-01726-y.","journal-title":"Drugs"},{"issue":"1","key":"509_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13023-019-1069-6","volume":"14","author":"RS Paquin","year":"2019","unstructured":"Paquin RS, Fischer R, Mansfield C, Mange B, Beaverson K, Ganot A, et al. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis. 2019;14(1):102. https:\/\/doi.org\/10.1186\/s13023-019-1069-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"509_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213649","volume":"14","author":"H Landrum Peay","year":"2019","unstructured":"Landrum Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Strong Martin A, et al. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS ONE. 2019;14(5): e0213649. https:\/\/doi.org\/10.1371\/journal.pone.0213649.","journal-title":"PLoS ONE"},{"issue":"5","key":"509_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1664","volume":"9","author":"HL Peay","year":"2021","unstructured":"Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, et al. Patients\u2019 and caregivers\u2019 maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021;9(5): e1664. https:\/\/doi.org\/10.1002\/mgg3.1664.","journal-title":"Mol Genet Genomic Med"},{"key":"509_CR13","unstructured":"IMI-PREFER. Patient preference studies. 2023. https:\/\/www.imi-prefer.eu\/case-studies\/how-to\/. Accessed 2 Mar 2023."},{"issue":"7","key":"509_CR14","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/wnl.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139. https:\/\/doi.org\/10.1212\/wnl.52.7.1487.","journal-title":"Neurology"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00509-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-023-00509-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-023-00509-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T12:14:24Z","timestamp":1706530464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-023-00509-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["509"],"URL":"https:\/\/doi.org\/10.1007\/s40290-023-00509-4","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"27 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding\/support"}},{"value":"This study was conducted under a research contract between UCB Pharma and RTI Health Solutions and was funded by UCB Pharma. Kerrie-Anne Ho, Meredin Stoltenberg, and Thais Tarancon are employees of UCB Pharma. Carol Mansfield and Anna Pierce are employees of RTI Health Solutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Authors affiliated with the study sponsor, UCB Pharma, participated in the design and conduct of the study; analysis and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of the Funder\/Sponsor"}},{"value":"The RTI International Institutional Review Board reviewed the study protocol for this case study and confirmed it exempt from full review.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All study participants provided informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Concept and design: K-AH, CM. Analysis and interpretation of data: K-AH, AP, MS, TT, CM. Critical revision of paper for important intellectual content: K-AH, AP, MS, TT, CM. Statistical analysis: AP, CM. Provision of study materials or patients: AP, CM. Obtaining funding: K-AH. Supervision: K-AH, CM. All authors have read and approved the final article.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}